Although in vitro and in vivo results suggest that the control of PAR1-mediated signaling may represent a promising strategy for the treatment of malignancy, currently only vorapaxar (SCH530348) is approved, as a PAR-1 antagonist, for patients with a history of myocardial infarction or peripheral arterial disease in the United States and with a history of myocardial infarction in Europe [109]. Here, F2R is linked to myocardial infarction.